中国实用儿科杂志

中国实用儿科杂志

• 论著 • 上一篇    下一篇

重组人干扰素α2b雾化治疗毛细支气管炎近期疗效与远期预后评价

  

  1. 重庆医科大学附属儿童医院呼吸中心，重庆　400014
  • 出版日期:2016-09-06 发布日期:2016-09-09

Clinical observation on aerosol inhalation of recombinant human interferon alpha 2b in treatment of bronchiolitis

  1. Respiratory Center，Children’s Hospital of Chongqing Medical University，Chongqing  400014，China
  • Online:2016-09-06 Published:2016-09-09

摘要：

目的    观察重组人干扰素α2b雾化治疗毛细支气管炎的临床疗效、对肺功能的影响及治疗后喘息情况。方法     收集2015年1月至2015年4月于重庆医科大学附属儿童医院呼吸中心门诊诊断的毛细支气管炎患儿100例， 男74例， 女26例。分两组， A组61例， 予重组人干扰素α2b 100万单位加生理盐水1 mL溶解后， 雾化吸入15～20 min， 每天1次， 疗程5～7 d； B组39例为对照组。两组均予止咳化痰、 解痉平喘对症治疗。治疗7 d后进行两组症状体、征消失时间及组间临床疗效比较。治疗后2个月行婴儿潮气呼吸肺功能检查， 观察两组呼吸频率（RR）、 潮气量（VT）、 达峰时间比（TPTEF/TE）、 达峰容积比（VPEF/VE）变化。并于6个月后电话随访患儿病后再次喘息情况。结果    A 组咳嗽、 喘憋、 肺部哮鸣音消失时间均早于 B组（P＜0.05）。A组治愈率（55.7%）高于 B组（17.9%），差异有统计学意义（χ2＝14.044，P＜0.05）。潮气呼吸肺功能比较提示，A组小气道阻塞轻于B组（P＜0.05）。A、B组再次喘息率分别为21.3%，28.2%，差异无统计学意义（χ2＝0.620，P＞0.05）。两组均未见局部刺激、皮疹、发热、呕吐等不良反应。结论    重组人干扰素α2b雾化吸入治疗毛细支气管炎临床疗效好，临床症状、体征消失早，呼吸肺功能检查小气道阻塞情况恢复较好，但对病后再次喘息的发生无明显改善。

关键词: 重组人干扰素&alpha, 2b, 婴儿, 毛细支气管炎, 雾化吸入

Abstract:

Objective    To observe the efficacy of aerosol inhalation of recombinant human interferon alpha 2b in treatment of bronchiolitis and its effects on the pulmonary function restoration and recurrent wheezing. Methods    A total of 100 outpatient infants diagnosed with bronchiolitis between January 2015 and April 2015 （74 males，26 females）were divided into 2 groups，61 cases in group A and 39 cases in group B. In addition to  the conventional therapy，group A had aerosol inhalation of recombinant human interferon alpha 2b for 5-7 days. Group B，as the control group，only had the conventional therapy. Then the curative effect after 7 days of treatment，time for clinical symptoms and signs to disappear，the tidal breathing pulmonary function about 2 months later and the incidence of recurrent wheezing of both group 6 months later were compared. Results    The curative effect，time for clinical symptoms and signs to disappear and tidal breathing pulmonary function （TPTEF/TE，VPEF/VE） of group A were significantly improved when compared with group B （P＜0.05），but the incidence of recurrent wheezing between group A and B had no significant difference（P＞0.05）. Conclusion    Aerosol inhalation of recombinant human interferon alpha 2b in treatment of bronchiolitis has good curative effect. This treatment can help clinical symptoms and signs to disappear early，help the early restoration of small airway obstruction，and mildly reduce the rate of  recurrent wheezing.

Key words: recombinant human interferon alpha 2b, infants, bronchiolitis, aerosol inhalation